71 related articles for article (PubMed ID: 38616999)
21. B7-H4 is a potential diagnostic and prognostic biomarker in colorectal cancer and correlates with the epithelial-mesenchymal transition.
Yan X; Hong B; Feng J; Jin Y; Chen M; Li F; Qian Y
BMC Cancer; 2022 Oct; 22(1):1053. PubMed ID: 36217128
[TBL] [Abstract][Full Text] [Related]
22. Non-small cell lung cancer in China.
Chen P; Liu Y; Wen Y; Zhou C
Cancer Commun (Lond); 2022 Oct; 42(10):937-970. PubMed ID: 36075878
[TBL] [Abstract][Full Text] [Related]
23. Inducible Co-Stimulator ICOS Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma.
Wu G; He M; Ren K; Ma H; Xue Q
Int J Gen Med; 2022; 15():3739-3751. PubMed ID: 35418779
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Patil NS; Nabet BY; Müller S; Koeppen H; Zou W; Giltnane J; Au-Yeung A; Srivats S; Cheng JH; Takahashi C; de Almeida PE; Chitre AS; Grogan JL; Rangell L; Jayakar S; Peterson M; Hsia AW; O'Gorman WE; Ballinger M; Banchereau R; Shames DS
Cancer Cell; 2022 Mar; 40(3):289-300.e4. PubMed ID: 35216676
[TBL] [Abstract][Full Text] [Related]
25. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E; McGlinchey K; Wang J; Martin P; Ching SL; Floc'h N; Kurasawa J; Starrett JH; Lazdun Y; Wetzel L; Nuttall B; Ng FS; Coffman KT; Smith PD; Politi K; Cooper ZA; Streicher K
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132961
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC.
Kojima K; Sakamoto T; Kasai T; Kagawa T; Yoon H; Atagi S
Sci Rep; 2021 Sep; 11(1):17522. PubMed ID: 34471191
[TBL] [Abstract][Full Text] [Related]
27. The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells.
Yan X; Feng J; Hong B; Qian Y
Front Oncol; 2021; 11():662010. PubMed ID: 34307135
[TBL] [Abstract][Full Text] [Related]
28. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
Li F; Deng L; Jackson KR; Talukder AH; Katailiha AS; Bradley SD; Zou Q; Chen C; Huo C; Chiu Y; Stair M; Feng W; Bagaev A; Kotlov N; Svekolkin V; Ataullakhanov R; Miheecheva N; Frenkel F; Wang Y; Zhang M; Hawke D; Han L; Zhou S; Zhang Y; Wang Z; Decker WK; Sonnemann HM; Roszik J; Forget MA; Davies MA; Bernatchez C; Yee C; Bassett R; Hwu P; Du X; Lizee G
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244308
[TBL] [Abstract][Full Text] [Related]
29. CD163-positive cancer cells are a predictor of a worse clinical course in lung adenocarcinoma.
Matsubara E; Komohara Y; Shinchi Y; Mito R; Fujiwara Y; Ikeda K; Shima T; Shimoda M; Kanai Y; Sakagami T; Suzuki M
Pathol Int; 2021 Oct; 71(10):666-673. PubMed ID: 34231937
[TBL] [Abstract][Full Text] [Related]
30. Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.
Perez-Santos M; Anaya-Ruiz M; Sanchez-Esgua G; Villafaña-Diaz L; Barron-Villaverde D
Pharm Pat Anal; 2021 Mar; 10(2):67-72. PubMed ID: 33829869
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
[TBL] [Abstract][Full Text] [Related]
32. Role of endocytosis and trans-endocytosis in ICOS costimulator-induced downmodulation of the ICOS Ligand.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; García-Paredes L; Arimura Y; Yagi J; Dianzani U; Portolés P; Rojo JM
J Leukoc Biol; 2021 Nov; 110(5):867-884. PubMed ID: 33527556
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
[TBL] [Abstract][Full Text] [Related]
34. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.
Li B; Zhu L; Lu C; Wang C; Wang H; Jin H; Ma X; Cheng Z; Yu C; Wang S; Zuo Q; Zhou Y; Wang J; Yang C; Lv Y; Jiang L; Qin W
Nat Commun; 2021 Jan; 12(1):295. PubMed ID: 33436560
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Associated Macrophages in Tumor Immunity.
Pan Y; Yu Y; Wang X; Zhang T
Front Immunol; 2020; 11():583084. PubMed ID: 33365025
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
Hwang I; Kim JW; Ylaya K; Chung EJ; Kitano H; Perry C; Hanaoka J; Fukuoka J; Chung JY; Hewitt SM
J Transl Med; 2020 Nov; 18(1):443. PubMed ID: 33228719
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.
Wu CE; Chang CF; Kou-Sheng L; Chiang J; Lee SW; Chiu YC
Anal Cell Pathol (Amst); 2020; 2020():3286139. PubMed ID: 33204603
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
39. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Rujas E; Cui H; Sicard T; Semesi A; Julien JP
Nat Commun; 2020 Oct; 11(1):5066. PubMed ID: 33033255
[TBL] [Abstract][Full Text] [Related]
40. ICOS
Li DY; Xiong XZ
Front Immunol; 2020; 11():2104. PubMed ID: 32983168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
